Omid Veiseh A

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

This paper demonstrates that localized cytokine-producing cells reduce fibrotic encapsulation and improve graft function in rodent models and a non-human primate.

This study develops SABER hydrogels that extend drug release and therapeutic effect for small molecules and biologics in preclinical models.

This study evaluates the pharmacokinetics of a human mAb in different mouse strains to identify suitable models for preclinical testing.

This paper develops a mathematical model to explain IL-12 pharmacokinetic desensitization, showing that reduced bioavailability, not increased clearance, best explains clinical data.

This paper introduces a genetic priming method using IRF1 to sustainably enhance MSC potency and suppress immunogenicity compared to biochemical priming.

This study shows that SMARCA4 regulates spatially restricted metabolic changes in 3D multicellular tissues by altering DNA accessibility and gene expression.